Protection of rabbits against rabbit viral haemorrhagic disease with a vaccinia-RHDV recombinant virus

Bertagnoli, Stéphane; Gelfi, Jacqueline; Petit, Fabienne; Vautherot, Jean-François; Rasschaert, Denis; Laurent, Sylvie; Gall, G Le; Boilletot, E.; Chantal, J.; Boucraut-Baralon, Corine

doi:10.1016/0264-410x(95)00232-p

Cited by 41 publications

(23 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Viruses used include VV (38), avipoxviruses (20), raccoon poxvirus (21), capripoxvirus (53), swinepox virus (58), and myxoma virus (4,27). Second, the expression of RHDV VP60 capsid protein in several heterologous systems has been shown to induce protective immunity (4,5,8,9,20,28). Remarkably, no indications of toxicity or side effects associated to the expression of VP60 have been reported.…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, the RHDV capsid protein gene has been successfully expressed in several heterologous systems. To date, VP60 protein has been produced in Escherichia coli (8); Saccharomyces cerevisiae (9), recombinant virus-based systems such as baculovirus (28,32,41,56) and poxvirus (4,5,20), and plants (12). The recombinant VP60 obtained in all these systems has been shown to induce protection of rabbits against a lethal challenge with RHDV.…”

mentioning

confidence: 99%

“…In some cases the recombinant VP60 protein selfassembled to form virus-like particles which were highly immunogenic (9,28,41,56). Both virus-like particles (50) and a recombinant vaccinia virus-VP60 virus (5) have been shown to confer protection against RHDV by the oral route.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Horizontal Transmissible Protection against Myxomatosis and Rabbit Hemorrhagic Disease by Using a Recombinant Myxoma Virus

Bárcena¹,

Morales²,

Vázquez³

et al. 2000

J Virol

View full text Add to dashboard Cite

We have developed a new strategy for immunization of wild rabbit populations against myxomatosis and rabbit hemorrhagic disease (RHD) that uses recombinant viruses based on a naturally attenuated field strain of myxoma virus (MV). The recombinant viruses expressed the RHDV major capsid protein (VP60) including a linear epitope tag from the transmissible gastroenteritis virus (TGEV) nucleoprotein. Following inoculation, the recombinant viruses induced specific antibody responses against MV, RHDV, and the TGEV tag. Immunization of wild rabbits by the subcutaneous and oral routes conferred protection against virulent RHDV and MV challenges. The recombinant viruses showed a limited horizontal transmission capacity, either by direct contact or in a flea-mediated process, promoting immunization of contact uninoculated animals.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Horizontal Transmissible Protection against Myxomatosis and Rabbit Hemorrhagic Disease by Using a Recombinant Myxoma Virus

Bárcena¹,

Morales²,

Vázquez³

et al. 2000

J Virol

View full text Add to dashboard Cite

show abstract

“…The vaccinia virus has a large number of genes which can be deleted without preventing replication in cell cultures and, in many cases, the deletion mutant has reduced virulence in animal models [18,77]. These genes have been applied as insertion sites for expression of foreign antigens and genes derived from a variety of pathogens have been stably introduced into the virus, providing potential recombinant vaccines for both veterinary and human applications, for example, genes from hepatitis B virus [76], human immunodeficiency virus (HIV) [18,129], HSV-1 [18], simian immunodeficiency virus [40], FIV [100], rabies virus [8], rinderpest virus [32], PRV [12], bovine ephemeral fever virus [36], and rabbit haemorrhagic disease virus [7]. Both humoral and cellular immune responses to the expression products from these recombinant vaccinia viruses have been demonstrated in animals and humans and, in many cases, their protective immunities have been induced in challenge studies.…”

Section: Recombinant Vaccinia Viruses 1 Vaccinia Virus Vectormentioning

confidence: 99%

Recombinant Viral Vector Vaccines for the Veterinary Use.

Yokoyama

Maeda

Mikami

1997

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Recently, genetically engineering using recombinant DNA techniques has been applied to design new viral vaccines in order to reduce some problems which present viral vaccines have. Up to now, many viruses have been investigated for development of recombinant attenuated vaccines or live viral vectors for delivery of foreign immunogenic antigens. In this review, we introduced three kind of viruses; herpesviruses, vaccinia viruses, and adenoviruses, which have best widely been studied as recombinant vaccines or delivery vaccines for the veterinary use. -KEY WORDS: recombinant polyvalent vaccine, recombinant vaccine, viral vector.

show abstract

“…Until now, the VP60 protein has been derived from diverse sources, such as recombinant virus based systems (Sibilia et al, 1995), which included baculoviruses (Nagesha et al, 1995), Escherichia coli (Bertagnoli et al, 1996), Saccharomyces cerevisiae (Boga et al, 1997) and pox viruses (Fischer et al, 1997), and even from plant sources (Castañón et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

Clinical chemistry, haematology, immune response and histological evaluation of rabbits after immunisation and challenge with rabbit haemorrhagic disease (RHD) virus

et al. 2017

View full text Add to dashboard Cite

Following their immunisation and infection with a VSHI-CN-6 viral strain, a group of 15 rabbits were examined in a study of Rabbit Haemorrhagic Disease (RHD). Serum samples were collected from the external ear vein at 0, 15, 30 and 60 days post-immunisation. The recorded platelet numbers were closer to the lower physiological limit, indicating a mild thrombocytopenia, with values ranging from 26.6 to 30.43×10 4 /mm 3 . The phagocytic index revealed significant differences (P<0.001) between the mean values obtained before vaccination (day 0) and the 3 post-vaccination measurements, confirming the increase in phagocytic capacity after immunisation. Additionally, the serum lysozyme average value equalled 9.14 mg/mL post-vaccination. The analysis of variance revealed significant statistical differences (P<0.05) between the average values obtained before vaccination (0) and the post-vaccination values, measured on day 14 and 30, respectively. The morphology of the samples collected from the main organs involved in immune protection, spleen and gastric and portal lymph nodes highlighted changes corresponding to the post-vaccination immunological response. The white pulp of the spleen appeared as a diffuse lymphoid tissue, presenting with primary and secondary lymphoid follicles. The ratio of white/red pulp was in favour of the white pulp and multiple lymphoid follicles were present, indicating their reactivation. In the medullary area of gastric and portal lymph nodes, narrow lymphoid cords, circumscribed by relatively large lymphatic sinuses, and well defined lymphocytolysis were observed. Moreover, the exudate and lymphoid follicles during activation were noted in the cortical area. Furthermore, the inflammatory processes were identified, morphologically manifested by the thickening of connective tissue in the lymph node capsule, dilacerations of the connective fibres and the presence of light acidophilic serous exudate with rare inflammatory cells (serous lymphoreticulitis).

show abstract

Protection of rabbits against rabbit viral haemorrhagic disease with a vaccinia-RHDV recombinant virus

Cited by 41 publications

References 17 publications

Horizontal Transmissible Protection against Myxomatosis and Rabbit Hemorrhagic Disease by Using a Recombinant Myxoma Virus

Horizontal Transmissible Protection against Myxomatosis and Rabbit Hemorrhagic Disease by Using a Recombinant Myxoma Virus

Recombinant Viral Vector Vaccines for the Veterinary Use.

Clinical chemistry, haematology, immune response and histological evaluation of rabbits after immunisation and challenge with rabbit haemorrhagic disease (RHD) virus

Contact Info

Product

Resources

About